Dear Editor,
We read with great interest the article by Lu et al. (1), recently published in the Korean Journal of Radiology, providing a comparison between the diagnostic performances of contrast-enhanced spectral mammography (CESM) and ultrasonography (US) in symptomatic patients with dense breasts, while using histology as the gold standard.
The authors highlighted the comparable diagnostic performances of CESM and US in symptomatic women with dense breasts in terms of sensitivity, specificity, positive predictive value, negative predictive value, and accuracy. Results of their study suggested the importance of the role of CESM in cases of women with dense or extremely dense breasts, where the diagnostic performance of full-field digital mammography could be lacking (2). Further, results of their study confirm that CESM could be greatly helpful for breast radiologists in the management of symptomatic patients, providing improved diagnostic and staging information at the first clinic visit (3).
However, data on comparison with size estimation of the breast lesion using pathological assessment of the resected specimen as the gold standard was lacking in their article: tumor size estimation plays a pivotal role in guiding the surgical management in breast cancer patients (4,5).
Dromain et al. (6) showed that CESM had the smallest difference in mean size estimation when compared with the pathological assessment of the resected specimen, while mammography and US showed underestimations.
We would like to take this opportunity to show the preliminary results of a prospective study that we are performing at our institute (European Institute of Oncology, 20141 Milano, Italy) in a cohort of 160 women with dense breasts investigated using CESM, US, full-field digital mammography, and magnetic resonance imaging preoperatively. In our experience, CESM is superior to full-field digital mammography and US and comparable to magnetic resonance imaging in terms of correct estimation of the lesion size, using the pathological assessment of the resected specimen as the gold standard.
In light of this, acknowledgement by the scientific community of the full potentiality of contrast-enhanced digital mammography is strongly advocated (7).
In the future, other multicentric prospective randomized trials on a larger cohort of patients are advised to gather sufficient data on use of CESM in daily clinical practice. Moreover, we think it could be useful in internationally connecting physicians who are involved in the study of CESM and are investigating its full potential, clinical applications, and future developments, such as the analysis of radiomic features of lesions (8).
References
- 1.Lu Z, Hao C, Pan Y, Mao N, Wang X, Yin X. Contrast-enhanced spectral mammography versus ultrasonography: diagnostic performance in symptomatic patients with dense breasts. Korean J Radiol. 2020;21:442–449. doi: 10.3348/kjr.2019.0393. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.James JJ, Tennant SL. Contrast-enhanced spectral mammography (CESM) Clin Radiol. 2018;73:715–723. doi: 10.1016/j.crad.2018.05.005. [DOI] [PubMed] [Google Scholar]
- 3.Patel BK, Lobbes MBI, Lewin J. Contrast enhanced spectral mammography: a review. Semin ultrasound CT MR. 2018;39:70–79. doi: 10.1053/j.sult.2017.08.005. [DOI] [PubMed] [Google Scholar]
- 4.Meier-Meitinger M, Rauh C, Adamietz B, Fasching PA, Schwab SA, Haeberle L, et al. Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients. Eur J Surg Oncol. 2012;38:44–51. doi: 10.1016/j.ejso.2011.10.008. [DOI] [PubMed] [Google Scholar]
- 5.Meier-Meitinger M, Häberle L, Fasching PA, Bani MR, Heusinger K, Wachter D, et al. Assessment of breast cancer tumour size using six different methods. Eur Radiol. 2011;21:1180–1187. doi: 10.1007/s00330-010-2016-z. [DOI] [PubMed] [Google Scholar]
- 6.Dromain C, Thibault F, Muller S, Rimareix F, Delaloge S, Tardivon A, et al. Dual-energy contrast-enhanced digital mammography: initial clinical results. Eur Radiol. 2011;21:565–574. doi: 10.1007/s00330-010-1944-y. [DOI] [PubMed] [Google Scholar]
- 7.Covington MF, Pizzitola VJ, Lorans R, Pockaj BA, Northfelt DW, Appleton CM, et al. The future of contrast-enhanced mammography. AJR Am J Roentgenol. 2018;210:292–300. doi: 10.2214/AJR.17.18749. [DOI] [PubMed] [Google Scholar]
- 8.Marino MA, Pinker K, Leithner D, Sung J, Avendano D, Morris EA, et al. Contrast-enhanced mammography and radiomics analysis for noninvasive breast cancer characterization: initial results. Mol Imaging Biol. 2020;22:780–787. doi: 10.1007/s11307-019-01423-5. [DOI] [PMC free article] [PubMed] [Google Scholar]